First patient treated in “miR-AGE” trial at University Hospital Center in Nice (CHU Nice)

50 study sites and 1,034 high-risk patients to participate in the European and Latin American placebo-controlled trial

ABX464 works via unique triple action: antiviral, anti-inflammatory and tissue repair

Easy, once daily oral administration allows inclusion of hospitalized as well as non-hospitalized COVID-19 patients

Results from this study expected by year-end